Loading…

Detection of a novel immunoreactive endomorphin 2-like peptide in rat brain extracts

To pursue further the possible de novo biosynthetic pathway of endomorphins in rat brain we raised antibodies to endomorphin-2 conjugate in rabbits. Antiserum R1 recognized endomorphin-2 with good selectivity as compared to endomorphin-1 with a median detection value of 65.5 ± 7.5 pg/tube ( n = 7),...

Full description

Saved in:
Bibliographic Details
Published in:Regulatory peptides 2008-06, Vol.148 (1), p.54-61
Main Authors: Szemenyei, Erzsébet, Barna, István, Mergl, Zsuzsa, Keresztes, Attila, Darula, Zsuzsanna, Kató, Erzsébet, Tóth, Géza, Rónai, András Z.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To pursue further the possible de novo biosynthetic pathway of endomorphins in rat brain we raised antibodies to endomorphin-2 conjugate in rabbits. Antiserum R1 recognized endomorphin-2 with good selectivity as compared to endomorphin-1 with a median detection value of 65.5 ± 7.5 pg/tube ( n = 7), whereas R4 antiserum recognized both endomorphins with similar sensitivity. Neither antisera recognized YP-related di- or tripeptides or YGGF-related opioid sequences (enkephalins, β-endorphin, dynorphin). Using the same rat brain extraction-RP-HPLC-gradient separation paradigm as previously, antisera detected 144.6 ± 40.0 ( n = 3) pg/g wet brain weight endomorphin-2-like immunoreactivity in the fraction corresponding to standard endomorphin-2 retention time and also in the fraction matching endomorphin-2-OH standard retention time (179.1 ± 30.1 pg/g). Since R1 failed to recognize authentic endomorphin-2-OH, the second immunoreactive species must be different from both endomorphin-2 and endomorphin-2-OH. Possible biosynthetic intermediates to endomorphins, synthetic YPFFG and YPWFG had retention times close to the parent endomorphin standards in RP-HPLC gradient separation profile. The former was a μ-opioid receptor agonist of medium potency in the in vitro assays (rat brain RBA&GTPγS binding and mouse vas deferens), whereas the latter was a weak μ-opioid receptor agonist with a significant δ-opioid receptorial action as well and a definite indication of partial agonism.
ISSN:0167-0115
1873-1686
DOI:10.1016/j.regpep.2008.03.001